HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission.

Abstract
Fifteen Hodgkin's disease patients (8 male, 7 female) aged 19-72 years, who had been in complete unmaintained remission for 1 year or more when the study was initiated, were given 50 mg thymostimulin (TS) IM daily for 60 consecutive days. When compared with 26-30 age- and sex-matched controls, as a group the patients' circulating ENR+, OKT+3, and OKT+4 cells were depressed (0.001 less than or equal to P less than or equal to 0.06), whereas their OKT+8 cell population was not. Low (greater than 1 SD or greater than 2 SD below mean in controls) or borderline (mean value of two subsequent tests greater than 1 SD below mean in controls) values of ENR+, OKT+3, and OKT+4 cells were seen in nine (group I) of the 15 patients tested, while the remaining six patients (group II) had normal T-cell proportions. Following TS treatment, the proportions of ENR+, OKT+3, and OKT+4 cells increased to normal in all group I patients. The T-cell levels, however, decreased to pretreatment values 60-70 days after completion of TS therapy. TS had no effect on the group II patients whose T-cell percentages had initially been normal. Spontaneous cell-mediated cytotoxicity (SCMC) was assessed in 11 patients, and irrespective of the baseline values, there was a significant enhancement (P less than 0.005) by day 15 of TS administration, which was maintained during treatment. SCMC, however, returned to pretreatment levels 60-70 days after TS was discontinued. The delayed skin test reactivity to DNCB was significantly depressed in all cases. Although TS restored the T-cell proportions, it failed to reverse DNCB reactivity from negative to positive in any of the patients tested. TS can thus restore defective T-cell frequencies and can enhance cytolytic functions that are potentially important in host immunosurveillance, but it apparently failed to improve the skin reactivity to neoantigen.
AuthorsA M Liberati, M Brugia, B S Edwards, P Bertoni, E Ballatori, A Puxeddu, F Grignani
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 19 Issue 2 Pg. 136-41 ( 1985) ISSN: 0340-7004 [Print] Germany
PMID3872709 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, Surface
  • Thymus Extracts
  • thymostimulin
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Antigens, Surface (analysis)
  • B-Lymphocytes (immunology)
  • Female
  • Hodgkin Disease (drug therapy, immunology)
  • Humans
  • Hypersensitivity, Delayed (immunology)
  • Lymphocytes (immunology)
  • Male
  • Middle Aged
  • T-Lymphocytes (immunology)
  • Thymus Extracts (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: